Hepatotoxicity with combination of vemurafenib and ipilimumab

N Engl J Med. 2013 Apr 4;368(14):1365-6. doi: 10.1056/NEJMc1302338.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • CTLA-4 Antigen / antagonists & inhibitors*
  • Chemical and Drug Induced Liver Injury / etiology*
  • Drug Therapy, Combination / adverse effects
  • Humans
  • Indoles / administration & dosage
  • Indoles / adverse effects*
  • Ipilimumab
  • Melanoma / drug therapy
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Sulfonamides / administration & dosage
  • Sulfonamides / adverse effects*
  • Vemurafenib

Substances

  • Antibodies, Monoclonal
  • CTLA-4 Antigen
  • Indoles
  • Ipilimumab
  • Protein Kinase Inhibitors
  • Sulfonamides
  • Vemurafenib
  • Proto-Oncogene Proteins B-raf